HC Wainwright & Co. Initiates Coverage On Clearside Biomedical with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Yi Chen initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Buy rating and announces Price Target of $10.